Journal of Veterinary Clinics (한국임상수의학회지)

The Korean Society of Veterinary Clinics (한국임상수의학회)
권호 표지
DOI QR코드

DOI QR Code

Evaluation on Clinical Application of Osmotic Pump with Dorzolamide in Normal Dogs

  • Kwon, Yonghwan (College of Veterinary Medicine, Chonbuk National University) ;
  • Kim, Jury (Bundang Bright-eye Animal Hospital) ;
  • Kim, Min-Su (Department of Veterinary Clinical Science, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University)
  • Received : 2019.11.17
  • Accepted : 2019.11.28
  • Published : 2019.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

This study was designed to compare the effects of continuous release of an anti-glaucoma drug applied by an osmotic pump and by conventional eye drop instillation in normal beagle dogs, by measuring drug concentration in the blood and monitoring intra-ocular pressure (IOP). In group 1, an osmotic pump filled with Trusopt® was implanted subcutaneously over the right eye of each dog and the IOP was measured. In group 2, the right eye of each dog was administered with 2% dorzolamide (Trusopt®, Merck, USA) three times per day. Blood was sampled once per week in all groups. The IOP of the end of this study was 16.7 ± 0.58 mmHg in group 2 and 17.7 ± 2.52 mmHg in group 2. Dorzolamide concentration in blood increased continuously over 4 weeks up to 585.8 ± 79.42 ㎍/L in group 1, and 747.3 ± 27.89 ㎍/L in group 2. We achieved satisfactory results in the osmotic pump group, which had a similar effect on IOP, and low fluctuations in IOP. Therefore, the results of this study should allow osmotic pumps to be consider as an alternative method to eye drops for the effective, safe, and convenient treatment of glaucoma.

키워드

참고문헌

  1. Agrahari V, Mandal A, Agrahari V, Trinh HM, Joseph M, Ray A, Hadji H, Mitra R, Pal D, Mitra AK, Agrahari V, Mandal A. A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res. 2016; 6: 735-754. https://doi.org/10.1007/s13346-016-0339-2
  2. Bae JH, Plummer CE, Kim J, Kim MS, Kim NS. Continuous ophthalmic treatment using an osmotic pump in a bull calf following surgical removal of an ocular dermoid: a case report. Vet Med Czech 2015; 60: 282-287.
  3. Bergea B, Bodin L, Svedbergh B. Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Ophthalmology 1999; 106: 997-1004. https://doi.org/10.1016/S0161-6420(99)00523-0
  4. Bertaud S, Aragno V, Baudouin C, Labbe A. Primary openangle glaucoma. Rev Med Interne 2019; 40: 445-452. https://doi.org/10.1016/j.revmed.2018.12.001
  5. Conlon R, Saheb H, Ahmed II. Glaucoma treatment trends: a review. Can J Ophthalmol 2017; 52: 114-124. https://doi.org/10.1016/j.jcjo.2016.07.013
  6. Hong S, Seong GJ, Hong YJ. Long-term intraocular pressure fluctuation and progressive visual field deterioration in patients with glaucoma and low intraocular pressures after a triple procedure. Arch of Ophthalmol 2007; 125: 1010-1013. https://doi.org/10.1001/archopht.125.8.1010
  7. Huang AS, Minasyan L, Weinreb RN. Glaucoma-Intraocular Pressure Reduction. Handb Exp Pharmacol 2017; 242: 181-207.
  8. Kim J, Kim MS. The evaluation of osmotic pump as glaucoma drug delivery system in normal dogs. Pak Vet J 2015; 35: 239-241.
  9. Lee DA, Higginbotham EJ. Glaucoma and its treatment: a review. Am J Health Syst Pharm 2005; 62: 691-699. https://doi.org/10.1093/ajhp/62.7.691
  10. Lee SS, Hughes P, Ross AD, Robinson MR. Biodegradable implants for sustained drug release in the eye. Pharm Res 2010; 27: 2043-2053. https://doi.org/10.1007/s11095-010-0159-x
  11. Lomelino C, McKenna R. Carbonic anhydrase inhibitors: a review on the progress of patent literature (2011-2016). Expert Opin Ther Pat 2016; 26: 947-956. https://doi.org/10.1080/13543776.2016.1203904
  12. Lusthaus J, Goldberg I. Current management of glaucoma. Med J Aust 2019; 210: 180-187. https://doi.org/10.5694/mja2.50020
  13. Mainardes RM, Urban MC, Cinto PO, Khalil NM, Chaud MV, Evangelista RC, Gremiao MP. Colloidal carriers for ophthalmic drug delivery. Curr Drug Targets 2005; 6: 363-371. https://doi.org/10.2174/1389450053765914
  14. McMonnies C. Reactive oxygen species, oxidative stress, glaucoma and hyperbaric oxygen therapy. J Optom 2018; 11: 3-9. https://doi.org/10.1016/j.optom.2017.06.002
  15. Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: An overview. World J Pharmacol 2013; 2: 47-64. https://doi.org/10.5497/wjp.v2.i2.47
  16. Phulke S, Kaushik S, Kaur S, Pandav SS. Steroid-induced glaucoma: An avoidable irreversible blindness. J Curr Glaucoma Pract 2017; 11: 67-72. https://doi.org/10.5005/jp-journals-10028-1226
  17. Pizzirani S. Definition, classification, and pathophysiology of canine glaucoma. Vet Clin North Am Small Anim Pract 2015; 45: 1127-1157. https://doi.org/10.1016/j.cvsm.2015.06.002
  18. Roy Chowdhury U, Hann CR, Stamer WD, Fautsch MP. Aqueous humor outflow: dynamics and disease. Invest Ophthalmol Vis Sci 2015; 56; 2993-3003. https://doi.org/10.1167/iovs.15-16744
  19. Rupenthal ID, Daugherty AL. Ocular drugs and drug delivery systems - Current trends and future perspectives. Drug Discov Today 2019; 24: 1425-1426. https://doi.org/10.1016/j.drudis.2019.07.005
  20. Russo R, Varano GP, Adornetto A, Nucci C, Corasaniti MT, Bagetta G, Morrone LA. Retinal ganglion cell death in glaucoma: Exploring the role of neuroinflammation. Eur J Pharmacol 2016; 15: 134-142.
  21. Sheshala R, Kok YY, Ng JM, Thakur RR, Dua K. In situ gelling ophthalmic drug delivery system: An overview and its applications. Recent Pat Drug Deliv Formul 2015; 9: 237-248.